Myoventive is a precision-cardiology therapeutics company developing next-generation RNA-based medicines to transform the treatment of genetic heart disease
Myoventive is a precision-cardiology therapeutics company developing next-generation RNA-based medicines to transform the treatment of genetic heart disease. Bringing together a seasoned leadership team with deep experience in RNA biology, antibody engineering, and drug development.